{"id":"h-p-acthar-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Mood changes / psychiatric effects"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased infection risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acthar contains adrenocorticotropic hormone (ACTH), which binds to melanocortin receptors on adrenocortical cells, triggering the synthesis and secretion of endogenous glucocorticoids and mineralocorticoids. This endogenous steroid production provides anti-inflammatory and immunosuppressive effects. Unlike exogenous corticosteroids, ACTH stimulates the adrenal gland directly, potentially offering a more physiologic hormonal response.","oneSentence":"H.P. Acthar Gel is a corticotropin (ACTH) preparation that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:30.528Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infantile spasms (West syndrome)"},{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Polymyositis and dermatomyositis"},{"name":"Acute exacerbations of multiple sclerosis"},{"name":"Nephrotic syndrome"}]},"trialDetails":[{"nctId":"NCT06964269","phase":"PHASE4","title":"Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease","status":"RECRUITING","sponsor":"Toyos Clinic","startDate":"2025-02-11","conditions":"Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis","enrollment":20},{"nctId":"NCT02226341","phase":"PHASE4","title":"ACTHar in the Treatment of Lupus Nephritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2014-10","conditions":"Lupus Nephritis","enrollment":8},{"nctId":"NCT01950234","phase":"PHASE2","title":"ACTH in Progressive Forms of MS","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2014-04-17","conditions":"Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis","enrollment":59},{"nctId":"NCT02245841","phase":"PHASE4","title":"Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2015-06-15","conditions":"Dermatomyositis, Juvenile Dermatomyositis","enrollment":19},{"nctId":"NCT03511625","phase":"PHASE3","title":"The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Attune Health Research, Inc.","startDate":"2018-10-02","conditions":"Rheumatoid Arthritis","enrollment":6},{"nctId":"NCT02725177","phase":"NA","title":"Ocular Sarcoidosis Open Label Trial of ACTHAR Gel","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2016-07","conditions":"Ocular Sarcoidosis, Panuveitis, Anterior Uveitis","enrollment":9},{"nctId":"NCT03465111","phase":"PHASE2","title":"A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis","status":"UNKNOWN","sponsor":"Metropolitan Eye Research & Surgery Institute","startDate":"2019-01-01","conditions":"Scleritis","enrollment":30},{"nctId":"NCT02030028","phase":"NA","title":"ACTH Gel Therapy in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Dana Ascherman","startDate":"2014-11","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT03727776","phase":"EARLY_PHASE1","title":"Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-08-19","conditions":"Proliferative Vitreoretinopathy","enrollment":11},{"nctId":"NCT02523092","phase":"PHASE4","title":"Use of CXCL9 as a Biomarker of Acthar Efficacy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-11-03","conditions":"Sarcoidosis","enrollment":14},{"nctId":"NCT01838174","phase":"PHASE4","title":"A Trial of Neuroprotection With ACTH in Acute Optic Neuritis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2013-05","conditions":"Multiple Sclerosis","enrollment":37},{"nctId":"NCT03320070","phase":"PHASE4","title":"Acthar Gel in Participants With Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-02-21","conditions":"Sarcoidosis, Pulmonary","enrollment":55},{"nctId":"NCT05546047","phase":"PHASE4","title":"A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients","status":"UNKNOWN","sponsor":"NephroNet, Inc.","startDate":"2019-03-14","conditions":"Fibrillary Glomerulonephritis","enrollment":34},{"nctId":"NCT02546492","phase":"PHASE4","title":"Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2016-08","conditions":"Transplant Glomerulopathy","enrollment":6},{"nctId":"NCT04080076","phase":"PHASE4","title":"Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy","status":"WITHDRAWN","sponsor":"NephroNet, Inc.","startDate":"2019-01-12","conditions":"Renal Disease","enrollment":""},{"nctId":"NCT03419650","phase":"PHASE4","title":"Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)","status":"COMPLETED","sponsor":"IRIS Research and Development, LLC","startDate":"2018-07-20","conditions":"Psoriatic Arthritis","enrollment":10},{"nctId":"NCT02399462","phase":"PHASE4","title":"Acthar for Treatment of Post-transplant FSGS","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-03","conditions":"FSGS, Renal Transplantation, Kidney Transplantation","enrollment":""},{"nctId":"NCT04169061","phase":"PHASE4","title":"Impact of Acthar on Everyday Life of Participants With Severe Keratitis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2019-11-13","conditions":"Keratitis","enrollment":36},{"nctId":"NCT02633046","phase":"PHASE4","title":"Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria","status":"COMPLETED","sponsor":"Mallinckrodt ARD LLC","startDate":"2016-10-10","conditions":"Idiopathic Focal Segmental Glomerulosclerosis","enrollment":63},{"nctId":"NCT03656692","phase":"PHASE4","title":"Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2018-10-05","conditions":"Uveitis, Posterior, Uveitis, Intermediate, Panuveitis","enrollment":5},{"nctId":"NCT03126760","phase":"PHASE4","title":"Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)","status":"TERMINATED","sponsor":"Mallinckrodt ARD LLC","startDate":"2017-05-22","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":35},{"nctId":"NCT02298491","phase":"PHASE4","title":"CNS Sarcoidosis and Acthar Gel","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-05","conditions":"CNS Sarcoidosis","enrollment":4},{"nctId":"NCT03042637","phase":"","title":"Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome","status":"SUSPENDED","sponsor":"Southeast Renal Research Institute","startDate":"2012-01","conditions":"Nephrotic Syndrome","enrollment":""},{"nctId":"NCT03287635","phase":"PHASE4","title":"Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2018-07-01","conditions":"Dry Eye Disease","enrollment":19},{"nctId":"NCT02446886","phase":"PHASE4","title":"Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2016-06","conditions":"Multiple Sclerosis","enrollment":15},{"nctId":"NCT00986960","phase":"PHASE2","title":"Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)","status":"WITHDRAWN","sponsor":"University at Buffalo","startDate":"2009-12","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT02920710","phase":"PHASE4","title":"ACTHAR Therapy for Central Nervous System Sarcoidosis","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2019-02-01","conditions":"Sarcoidosis","enrollment":""},{"nctId":"NCT03068754","phase":"PHASE2, PHASE3","title":"Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2017-06-22","conditions":"Amyotrophic Lateral Sclerosis","enrollment":143},{"nctId":"NCT02057523","phase":"PHASE4","title":"Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2014-09","conditions":"Proteinuria, Transplant Glomerulopathy","enrollment":2},{"nctId":"NCT02953821","phase":"PHASE4","title":"Acthar Gel for Active Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2016-12-16","conditions":"Lupus Erythematosus, Systemic","enrollment":172},{"nctId":"NCT02290444","phase":"PHASE3","title":"Effects of Acthar on Recovery From Cognitive Relapses in MS","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2013-08","conditions":"Multiple Sclerosis","enrollment":64},{"nctId":"NCT02919761","phase":"PHASE4","title":"Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2016-11-07","conditions":"Arthritis, Rheumatoid","enrollment":259},{"nctId":"NCT01753401","phase":"PHASE4","title":"Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2013-01","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":38},{"nctId":"NCT03644771","phase":"","title":"Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function","status":"UNKNOWN","sponsor":"Greater Boston Medical Associates","startDate":"2017-01-25","conditions":"Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function","enrollment":40},{"nctId":"NCT02633033","phase":"","title":"Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2015-11-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":160},{"nctId":"NCT01386554","phase":"PHASE4","title":"Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2011-08","conditions":"Proteinuria, Idiopathic Membranous Nephropathy","enrollment":60},{"nctId":"NCT01601236","phase":"PHASE2","title":"Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2012-05","conditions":"Diabetic Nephropathy","enrollment":34},{"nctId":"NCT02779153","phase":"PHASE4","title":"Acthar SLE (Systemic Lupus Erythematosus)","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-10","conditions":"Systemic Lupus Erythematosus (SLE), Repository Corticotropin Injection","enrollment":""},{"nctId":"NCT03066869","phase":"PHASE4","title":"Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis","status":"UNKNOWN","sponsor":"Ocular Immunology and Uveitis Foundation","startDate":"2017-03-22","conditions":"Uveitis, Posterior, Vasculitis Retinal","enrollment":40},{"nctId":"NCT02315872","phase":"PHASE3","title":"ACTH for Fatigue in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2015-05-22","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":8},{"nctId":"NCT02282930","phase":"PHASE3","title":"Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-03","conditions":"Progressive IgA Nephropathy, Proteinuria","enrollment":20},{"nctId":"NCT03408405","phase":"PHASE4","title":"ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2018-06","conditions":"Steroid-Resistant Nephrotic Syndrome","enrollment":""},{"nctId":"NCT03398018","phase":"PHASE4","title":"Repository Corticotropin Injection in Keratoconjunctivitis Sicca","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2018-11-01","conditions":"Keratoconjunctivitis Sicca","enrollment":""},{"nctId":"NCT01367964","phase":"NA","title":"Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)","status":"UNKNOWN","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2011-07","conditions":"West Syndrome","enrollment":28},{"nctId":"NCT02769702","phase":"PHASE4","title":"Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-06","conditions":"Uveitis","enrollment":2},{"nctId":"NCT01813591","phase":"PHASE2","title":"A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines","status":"COMPLETED","sponsor":"Dent Neuroscience Research Center","startDate":"2013-04","conditions":"Chronic Migraine","enrollment":20},{"nctId":"NCT02764697","phase":"PHASE4","title":"Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients","status":"COMPLETED","sponsor":"Tampa Bay Uveitis Center, LLC","startDate":"2016-06-30","conditions":"Uveitis, Anterior Uveitis, Intermediate Uveitis","enrollment":6},{"nctId":"NCT01926054","phase":"PHASE4","title":"ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis","status":"WITHDRAWN","sponsor":"Ohio State University","startDate":"2013-07","conditions":"SLE Glomerulonephritis Syndrome, WHO Class V","enrollment":""},{"nctId":"NCT03473964","phase":"","title":"(ACTH) for the Treatment of Sarcoid Uveitis","status":"UNKNOWN","sponsor":"John Huang, MD","startDate":"2018-04-01","conditions":"Sarcoid Uveitis","enrollment":10},{"nctId":"NCT02113735","phase":"PHASE2","title":"Safety and Efficacy Study of Acthar in Subjects With ARDS","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2014-08","conditions":"Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT01900093","phase":"NA","title":"Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses","status":"UNKNOWN","sponsor":"Aaron Miller","startDate":"2013-07","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT01906372","phase":"PHASE2","title":"Acthar in Treatment of Refractory Dermatomyositis and Polymyositis","status":"COMPLETED","sponsor":"Rohit Aggarwal, MD","startDate":"2013-09","conditions":"Dermatomyositis, Polymyositis","enrollment":12},{"nctId":"NCT01093157","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-02","conditions":"Glomerulonephritis","enrollment":10},{"nctId":"NCT01049451","phase":"PHASE1","title":"Pulse ACTH vs. MP for MS","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2009-11","conditions":"Multiple Sclerosis","enrollment":23},{"nctId":"NCT02382523","phase":"PHASE4","title":"Acthar on Proteinuria in IgA Nephropathy Patients","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"IgA Nephropathy, Proteinuria","enrollment":""},{"nctId":"NCT03082573","phase":"PHASE4","title":"Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel","status":"UNKNOWN","sponsor":"Iraj Sabahi Research Inc.","startDate":"2017-03-03","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT02486744","phase":"PHASE1","title":"Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population","status":"TERMINATED","sponsor":"Youngstown State University","startDate":"2015-03","conditions":"End Stage Renal Disease","enrollment":9},{"nctId":"NCT01906658","phase":"PHASE2","title":"A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2013-07","conditions":"Amyotrophic Lateral Sclerosis","enrollment":43},{"nctId":"NCT01966718","phase":"PHASE4","title":"Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.","status":"COMPLETED","sponsor":"Arthritis Treatment Center, Maryland","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT02574962","phase":"PHASE2","title":"Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy","status":"WITHDRAWN","sponsor":"Mamatha Pasnoor, MD","startDate":"2015-08","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":""},{"nctId":"NCT00947895","phase":"PHASE2, PHASE3","title":"Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone","status":"TERMINATED","sponsor":"Neurologique Foundation, Inc.","startDate":"2009-10","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT02188017","phase":"PHASE4","title":"Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2014-06","conditions":"Sarcoidosis, Pulmonary Sarcoidosis","enrollment":20},{"nctId":"NCT02434757","phase":"NA","title":"Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Ronald J. Rapoport, MD","startDate":"2014-02","conditions":"Rheumatoid Arthritis","enrollment":10},{"nctId":"NCT02348905","phase":"PHASE2, PHASE3","title":"ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial","status":"UNKNOWN","sponsor":"Albany Medical College","startDate":"2015-03","conditions":"Sarcoidosis, Cutaneous Sarcoidosis","enrollment":10},{"nctId":"NCT02155803","phase":"PHASE2, PHASE3","title":"ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study","status":"UNKNOWN","sponsor":"Albany Medical College","startDate":"2015-02","conditions":"Sarcoidosis, Hypercalcemia Due to Sarcoidosis","enrollment":10},{"nctId":"NCT00805753","phase":"PHASE1","title":"Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-01","conditions":"Idiopathic Membranous Nephropathy","enrollment":20},{"nctId":"NCT01888354","phase":"PHASE4","title":"Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-04","conditions":"Multiple Sclerosis (MS)","enrollment":25},{"nctId":"NCT01155141","phase":"PHASE4","title":"Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Kidney Diseases","enrollment":15},{"nctId":"NCT01129284","phase":"PHASE4","title":"Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2009-12","conditions":"Treatment Resistant Nephrotic Syndrome","enrollment":15},{"nctId":"NCT01939132","phase":"PHASE4","title":"Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis","status":"UNKNOWN","sponsor":"Fiechtner, Justus J., M.D., P.C.","startDate":"2013-07","conditions":"Psoriatic Arthritis","enrollment":10},{"nctId":"NCT01906684","phase":"NA","title":"Comprehensive Analysis of Relapse in Multiple Sclerosis","status":"UNKNOWN","sponsor":"Tanner Foundation for Multiple Sclerosis","startDate":"2013-08","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01769937","phase":"PHASE4","title":"Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Fiechtner, Justus J., M.D., P.C.","startDate":"2012-10","conditions":"Lupus Erythematosus Systemic Exacerbation","enrollment":10},{"nctId":"NCT01028287","phase":"PHASE4","title":"Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)","status":"COMPLETED","sponsor":"Southeast Renal Research Institute","startDate":"2009-05","conditions":"Diabetic Nephropathy, Nephrotic Syndrome","enrollment":15},{"nctId":"NCT01021540","phase":"PHASE4","title":"Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes","status":"COMPLETED","sponsor":"Arizona Kidney Disease and Hypertension Center","startDate":"2009-12","conditions":"Nephrotic Syndromes","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"DYSPNOEA"},{"count":6,"reaction":"ATRIAL FIBRILLATION"},{"count":5,"reaction":"ANAEMIA"},{"count":5,"reaction":"DEHYDRATION"},{"count":5,"reaction":"HYPERTENSION"},{"count":5,"reaction":"RENAL FAILURE ACUTE"},{"count":5,"reaction":"VOMITING"},{"count":4,"reaction":"ABDOMINAL PAIN"},{"count":4,"reaction":"FLUID RETENTION"},{"count":4,"reaction":"OEDEMA"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACTH","Acthar","Repository Corticotropin Injection","ACTH Gel","Acthar Gel"],"phase":"marketed","status":"active","brandName":"H.P. Acthar Gel","genericName":"H.P. Acthar Gel","companyName":"Fiechtner, Justus J., M.D., P.C.","companyId":"fiechtner-justus-j-m-d-p-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"H.P. Acthar Gel is a corticotropin (ACTH) preparation that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids. Used for Infantile spasms (West syndrome), Rheumatoid arthritis, Systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}